[go: up one dir, main page]

WO2014080307A3 - Compositions and methods for the treatment of diabetes and pre-diabetes - Google Patents

Compositions and methods for the treatment of diabetes and pre-diabetes Download PDF

Info

Publication number
WO2014080307A3
WO2014080307A3 PCT/IB2013/059680 IB2013059680W WO2014080307A3 WO 2014080307 A3 WO2014080307 A3 WO 2014080307A3 IB 2013059680 W IB2013059680 W IB 2013059680W WO 2014080307 A3 WO2014080307 A3 WO 2014080307A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
treatment
methods
compositions
prediabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2013/059680
Other languages
French (fr)
Other versions
WO2014080307A2 (en
Inventor
Mahesh Kandula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/IB2014/058634 priority Critical patent/WO2014195810A2/en
Priority to AU2014276346A priority patent/AU2014276346A1/en
Priority to CA2914461A priority patent/CA2914461A1/en
Priority to PCT/IN2014/000089 priority patent/WO2014195961A1/en
Priority to SG11201509782TA priority patent/SG11201509782TA/en
Priority to EP14725542.6A priority patent/EP3004049B1/en
Priority to US14/244,911 priority patent/US8952068B2/en
Publication of WO2014080307A2 publication Critical patent/WO2014080307A2/en
Publication of WO2014080307A3 publication Critical patent/WO2014080307A3/en
Priority to US14/583,117 priority patent/US9174931B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C07C313/04—Sulfinic acids; Esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/08—Sulfenic acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/30—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A composition which includes a salt of metformin and the use of the composition for the treatment of or use in prediabetes, diabetes, lowering triglycerides and metabolic syndrome. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.
PCT/IB2013/059680 2012-11-21 2013-10-26 Compositions and methods for the treatment of diabetes and pre-diabetes Ceased WO2014080307A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
PCT/IB2014/058634 WO2014195810A2 (en) 2013-06-04 2014-01-29 Compositions and methods for the treatment of diabetes and pre-diabetes
EP14725542.6A EP3004049B1 (en) 2013-06-04 2014-02-12 Compositions and methods for the treatment of diabetes and pre-diabetes
CA2914461A CA2914461A1 (en) 2013-06-04 2014-02-12 Compositions and methods for the treatment of diabetes and pre-diabetes
PCT/IN2014/000089 WO2014195961A1 (en) 2013-06-04 2014-02-12 Compositions and methods for the treatment of diabetes and pre-diabetes
SG11201509782TA SG11201509782TA (en) 2013-06-04 2014-02-12 Compositions and methods for the treatment of diabetes and pre-diabetes
AU2014276346A AU2014276346A1 (en) 2013-06-04 2014-02-12 Compositions and methods for the treatment of diabetes and pre-diabetes
US14/244,911 US8952068B2 (en) 2013-06-04 2014-04-04 Compositions for the treatment of diabetes and pre-diabetes
US14/583,117 US9174931B2 (en) 2013-06-04 2014-12-25 Compositions for the treatment of diabetes and pre-diabetes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN4858/CHE/2012 2012-11-21
IN4858CH2012 2012-11-21

Publications (2)

Publication Number Publication Date
WO2014080307A2 WO2014080307A2 (en) 2014-05-30
WO2014080307A3 true WO2014080307A3 (en) 2014-12-24

Family

ID=50776623

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/059680 Ceased WO2014080307A2 (en) 2012-11-21 2013-10-26 Compositions and methods for the treatment of diabetes and pre-diabetes

Country Status (1)

Country Link
WO (1) WO2014080307A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2914461A1 (en) * 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
EP3248961B1 (en) * 2015-01-19 2019-12-25 Showa Denko K.K. Compound, salt of compound, external agent for skin, cosmetic, and food additive
KR20210113184A (en) * 2018-11-30 2021-09-15 코멧 테라퓨틱스, 인코포레이티드 Cyclic pantethane derivatives and uses thereof
EP4192441A1 (en) * 2020-08-06 2023-06-14 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Oleylcysteineamide or derivatives thereof and their use in therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120178813A1 (en) * 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120178813A1 (en) * 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent

Also Published As

Publication number Publication date
WO2014080307A2 (en) 2014-05-30

Similar Documents

Publication Publication Date Title
WO2012019426A8 (en) Phthalazinone derivative, and preparation method and pharmaceutical use thereof
WO2012019430A8 (en) Phthalazinone derivative, and preparation method and pharmaceutical use thereof
CL2014001437A1 (en) Compounds derived from aryl dihydropyridinone and piperidinone as inhibitors of monoacrylic glycerol acyltransferase (mgat2); pharmaceutical composition and combination; and use in the treatment and prevention of diabetes, hyperglycemia, retinopathy, metabolic syndrome, among other diseases.
WO2013123215A3 (en) Antiviral drugs for treatment of arenavirus infection
CL2013003025A1 (en) Compounds derived from diaminocarboxamide and diaminocarbonitrile pyrimidines, such as jnk kinase inhibitors; pharmaceutical composition; in vitro inhibition method; and its use in the treatment or prevention of fibrotic liver disorders, diabetes or metabolic syndrome leading to fibrotic liver disorders.
WO2012117000A8 (en) 3-amino-pyridines as gpbar1 agonists
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
DK2395979T3 (en) ORAL DOSAGE COMPOSITIONS WITH DELAYED DELIVERY CONTAINING AMORFT CCDO-ME
HRP20161261T8 (en) Nitrocatechol derivates as comt inhibitors administered with a specific dosage regime
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
IL226386A0 (en) Therapeutic treatment for metabolic syndrome, type 2 diabetes, obestiy or prediabetes
BRPI0917502A2 (en) pharmaceutical composition, and methods for using an organic acid or antioxidant, to prevent discoloration caused when tranemaxamic acid and ascorbic acid are incorporated into the same composition, and to produce a solid pharmaceutical preparation for oral administration.
WO2013175376A3 (en) Compositions and methods for the treatment of local pain
WO2014068463A3 (en) Compositions and methods for the treatment of inflammation and metabolic disorders
WO2014087307A3 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
WO2014080307A3 (en) Compositions and methods for the treatment of diabetes and pre-diabetes
WO2016046680A3 (en) Compositions and methods for the treatment of liver metabolic diseases
WO2014091384A3 (en) Compositions and methods for the treatment of mucositis
MX2013008256A (en) Novel tetrahydroquinoline derivatives.
WO2013175359A3 (en) Compositions and methods for the treatment of multiple sclerosis
WO2014087323A3 (en) Compounds and compositions for the treatment of autoimmune and chronic metabolic diseases
WO2012175996A3 (en) Drug delivery formulations
WO2013175344A3 (en) Compositions and methods for treatment of peridontitis and rheumatoid arthritis
WO2014106804A3 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
WO2014195810A3 (en) Compositions and methods for the treatment of diabetes and pre-diabetes

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 13856352

Country of ref document: EP

Kind code of ref document: A2